Reuters logo
BRIEF-Spark Therapeutics enters licensing agreement with Selecta Biosciences
December 5, 2016 / 12:22 PM / 9 months ago

BRIEF-Spark Therapeutics enters licensing agreement with Selecta Biosciences

Dec 5 (Reuters) - Spark Therapeutics Inc

* Spark Therapeutics enters into licensing agreement with Selecta Biosciences

* Will make an initial $10 million cash payment to Selecta and purchase $5 million of Selecta’s common stock

* Spark Therapeutics - within 12 months of agreement, agreed to pay Selecta additional $5 million in cash and to purchase $10 million of Selecta’s common stock

* Selecta will be eligible for up to $430 million in milestone payments for each target

* Spark Therapeutics - in addition, will pay Selecta mid-single to low-double-digit royalties on worldwide annual sales of commercialized gene therapy Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below